Influenza
Conditions
Keywords
Influenza vaccine GSK576389A, Fluarix, Influenza infection
Brief summary
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after repeated vaccine administration. In this study, the subjects previously enrolled in study 104887 will receive a dose with the 2007-2008 season's formulations of Fluarix or GSK576389A. Only subjects who were previously enrolled in study 104887 are eligible for participation in this study.
Detailed description
This study is a year 2 revaccination study. First year revaccination was done in study 104887 (NCT00386698). Primary study was study 104886 (NCT00318149). This study involves 2 age groups (based on primary study): Subjects enrolled in the ≥ 65 years age group in the primary study. Subjects enrolled in the 18-40 years age group in the primary study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007
Interventions
BIOLOGICALFluarix™
Single dose, Intramuscular injection
BIOLOGICALGSK Bio's Influenza Vaccine GSK576389A
Single dose, Intramuscular injection
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Subjects who were previously vaccinated with GlaxoSmithKline Biologicals Fluarix™ or GSK576389A investigational vaccines in the 104887 study (NCT00386698). * Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. * A male or female aged between 19 and 42 years or 66 years and older at the time of the vaccination. * Written informed consent obtained from the subject. * Free of an acute aggravation of the health status as established by clinical evaluation before entering into the study. * If the subject is female, she must be of non-childbearing potential or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.
Exclusion criteria
* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days prior to vaccination, or planned use during the study period. * Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. Planned administration of a vaccine not foreseen by the study protocol up to 21 days after vaccination. * Planned administration of an influenza vaccine other than the study vaccines during the entire study period. * Vaccination against influenza since January 2007 with the Northern Hemisphere 2007/2008 influenza vaccine or 2006/2007 influenza vaccine. * History of confirmed influenza infection since the date of previous vaccination. * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the administration of the study vaccine. (For corticosteroids, this will mean prednisone, or equivalent, ≥0.5 mg/kg/day. Inhaled and topical steroids are allowed.) * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). * History of hypersensitivity to a previous dose of influenza vaccine. * History of allergy or reactions likely to be exacerbated by any component of the vaccine(s) * Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by clinical evaluation (medical history and medical history directed physical examination) or pre-existing laboratory screening tests. * Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e. Axillary temperature \<37.5°C / Oral temperature of \<37.5°C). * Administration of immunoglobulins and/or any blood products within the three months preceding the first administration of the study vaccine or planned administration during the study. * Any medical conditions in which intramuscular injections are contraindicated. * Pregnant or lactating female. * Female planning to become pregnant or planning to discontinue contraceptive precautions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | Day 0-20 | SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination. |
| Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Day 0-6 | Grade 3 ecchymosis, redness and swelling was greater than 100 millimeter i.e. \>100 mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade. |
| Duration of Solicited Local AEs | Day 0-6 | Duration was defined as number of days with any grade of local symptoms. |
| Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Day 0-6 | Any temperature was defined as axillary temperature ≥38.0 degree centigrade (°C), grade 3 temperature was axillary temperature ≥39.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as general symptom that prevented normal activity. Related was general symptom assessed by the investigator as causally related to the study vaccination. |
| Duration of Solicited General AEs | Day 0-6 | Duration was defined as number of days with any grade of general symptoms. |
| Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Day 0-20 | Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was event that prevented normal activities and related was defined as unsolicited AE assessed by the investigator to be causally related to the study vaccination. |
| Number of Subjects Reporting at Least One, Grade 3 and Related Medically Significant Conditions (MSCs) | Day 0-20 | MSCs were defined as AEs with a medically-attended visit i.e. prompting emergency room (ER) visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination. At least one MSC was defined as at least one MSC experienced. Grade 3 was MSC that prevented normal activities and Related was defined as MSC assessed by the investigator to be causally related to the study vaccination. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The Number of Subjects Seropositive to HI Antibodies | At Days 0 and 21 | Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e. ≥ 1:10. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| Haemagglutination Inhibition (HI) Antibody Titers | At Days 0 and 21 | Antibody titers were expressed as Geometric mean titers (GMTs). The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| The Number of Subjects Seroconverted to HI Antibodies | At Day 21 | Seroconversion was defined as either a pre-vaccination titer \<1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| HI Antibody Seroconversion Factors (SCF) | At Day 21 | SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| The Number of Subjects Seroprotected to HI Antibodies | At Days 0 and 21 | Seroprotection was defined as serum HI titer ≥1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens. |
| The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | At Days 0 and 21 | The vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and Pool FLU antigens and the markers assessed were Cluster of Differentiation 4-All doubles i.e. CD4-All doubles, CD40 Ligand (CD40L), interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α). |
| The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | At Days 0 and 21 | The vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and Pool FLU antigens and the markers assessed were CD8-All doubles, CD40L, IFN-γ, IL-2 and TNF-α. |
Countries
Belgium
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group Subjects aged ≥ 66 years who previously received 1 dose of adjuvanted influenza vaccine GSK576389A in NCT00318149 and NCT00386698 studies were administered 1 dose of adjuvanted influenza vaccine GSK576389A. | 55 |
| Fluarix Elderly Group Subjects aged ≥ 66 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine. | 40 |
| Fluarix Young Group Subjects aged 19-42 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine. | 38 |
| Total | 133 |
Baseline characteristics
| Characteristic | Adjuvanted Influenza Vaccine GSK576389A Group | Fluarix Elderly Group | Fluarix Young Group | Total |
|---|---|---|---|---|
| Age, Continuous | 71.2 Years STANDARD_DEVIATION 3.07 | 71.2 Years STANDARD_DEVIATION 3.47 | 27.4 Years STANDARD_DEVIATION 6.08 | 58.69 Years STANDARD_DEVIATION 20.3 |
| Sex: Female, Male Female | 22 Participants | 17 Participants | 16 Participants | 55 Participants |
| Sex: Female, Male Male | 33 Participants | 23 Participants | 22 Participants | 78 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 46 / 55 | 24 / 40 | 36 / 38 |
| serious Total, serious adverse events | 0 / 55 | 0 / 40 | 0 / 38 |
Outcome results
Primary
Duration of Solicited General AEs
Duration was defined as number of days with any grade of general symptoms.
Time frame: Day 0-6
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group | Duration of Solicited General AEs | Shivering (N=10; 0; 2) | 1.0 Days |
| Adjuvanted Influenza Vaccine GSK576389A Group | Duration of Solicited General AEs | Myalgia (N=10; 3; 10) | 2.0 Days |
| Adjuvanted Influenza Vaccine GSK576389A Group | Duration of Solicited General AEs | Headache (N=13; 5; 8) | 1.0 Days |
| Adjuvanted Influenza Vaccine GSK576389A Group | Duration of Solicited General AEs | Fatigue (N=19; 6; 9) | 2.0 Days |
| Adjuvanted Influenza Vaccine GSK576389A Group | Duration of Solicited General AEs | Nausea (N=4; 0; 3) | 1.0 Days |
| Adjuvanted Influenza Vaccine GSK576389A Group | Duration of Solicited General AEs | Temperature (N=4; 0; 0) | 1.0 Days |
| Adjuvanted Influenza Vaccine GSK576389A Group | Duration of Solicited General AEs | Arthralgia (N=6; 6; 2) | 2.5 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Headache (N=13; 5; 8) | 1.0 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Fatigue (N=19; 6; 9) | 1.0 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Temperature (N=4; 0; 0) | NA Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Arthralgia (N=6; 6; 2) | 2.0 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Myalgia (N=10; 3; 10) | 2.0 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Nausea (N=4; 0; 3) | NA Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Shivering (N=10; 0; 2) | NA Days |
| Fluarix Young Group | Duration of Solicited General AEs | Myalgia (N=10; 3; 10) | 2.0 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Temperature (N=4; 0; 0) | NA Days |
| Fluarix Young Group | Duration of Solicited General AEs | Shivering (N=10; 0; 2) | 3.5 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Nausea (N=4; 0; 3) | 1.0 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Headache (N=13; 5; 8) | 2.0 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Arthralgia (N=6; 6; 2) | 1.5 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Fatigue (N=19; 6; 9) | 2.0 Days |
Primary
Duration of Solicited Local AEs
Duration was defined as number of days with any grade of local symptoms.
Time frame: Day 0-6
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented and symptom sheet completed only on subjects that reported the specific symptom.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group | Duration of Solicited Local AEs | Redness (N=13; 6; 1) | 3.0 Days |
| Adjuvanted Influenza Vaccine GSK576389A Group | Duration of Solicited Local AEs | Pain (N=40; 12; 34) | 2.0 Days |
| Adjuvanted Influenza Vaccine GSK576389A Group | Duration of Solicited Local AEs | Swelling (N=6; 4; 0) | 3.0 Days |
| Fluarix Elderly Group | Duration of Solicited Local AEs | Redness (N=13; 6; 1) | 1.0 Days |
| Fluarix Elderly Group | Duration of Solicited Local AEs | Pain (N=40; 12; 34) | 1.5 Days |
| Fluarix Elderly Group | Duration of Solicited Local AEs | Swelling (N=6; 4; 0) | 1.0 Days |
| Fluarix Young Group | Duration of Solicited Local AEs | Pain (N=40; 12; 34) | 2.0 Days |
| Fluarix Young Group | Duration of Solicited Local AEs | Swelling (N=6; 4; 0) | NA Days |
| Fluarix Young Group | Duration of Solicited Local AEs | Redness (N=13; 6; 1) | 1.0 Days |
Primary
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Grade 3 ecchymosis, redness and swelling was greater than 100 millimeter i.e. \>100 mm and grade 3 pain was considerable pain at rest that prevented normal everyday activities. Any was occurrence of any local symptom regardless of their intensity grade.
Time frame: Day 0-6
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 0 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 13 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 0 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 40 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 0 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 6 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 4 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 12 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 6 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 1 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 34 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 0 subjects |
Primary
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade and related was event assessed by the investigator as causally related to the study vaccination.
Time frame: Day 0-20
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | Any SAE(s) | 0 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | Related SAE(s) | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | Related SAE(s) | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | Any SAE(s) | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | Any SAE(s) | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | Related SAE(s) | 0 subjects |
Primary
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Any temperature was defined as axillary temperature ≥38.0 degree centigrade (°C), grade 3 temperature was axillary temperature ≥39.0°C. For other symptoms, any was defined as occurrence of any general symptom regardless of intensity grade or relation to vaccination and grade 3 was defined as general symptom that prevented normal activity. Related was general symptom assessed by the investigator as causally related to the study vaccination.
Time frame: Day 0-6
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 4 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 11 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any nausea | 4 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 19 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 9 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 10 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 0 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 19 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 10 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 0 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 0 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 0 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 0 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related temperature | 4 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 13 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 6 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 10 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any temperature | 4 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 temperature | 0 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related nausea | 4 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 nausea | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 3 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 nausea | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 6 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 3 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 6 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 3 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 5 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 2 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 1 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any nausea | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related nausea | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any temperature | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 temperature | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related temperature | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any nausea | 3 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 2 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related nausea | 1 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 2 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 nausea | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 2 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 10 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related temperature | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 1 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 8 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 8 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 7 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 temperature | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 1 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 9 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 10 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 2 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any temperature | 0 subjects |
Primary
Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was event that prevented normal activities and related was defined as unsolicited AE assessed by the investigator to be causally related to the study vaccination.
Time frame: Day 0-20
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 1 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 18 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 6 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 1 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 9 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 2 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 19 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 3 subjects |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 1 subjects |
Primary
Number of Subjects Reporting at Least One, Grade 3 and Related Medically Significant Conditions (MSCs)
MSCs were defined as AEs with a medically-attended visit i.e. prompting emergency room (ER) visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination. At least one MSC was defined as at least one MSC experienced. Grade 3 was MSC that prevented normal activities and Related was defined as MSC assessed by the investigator to be causally related to the study vaccination.
Time frame: Day 0-20
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting at Least One, Grade 3 and Related Medically Significant Conditions (MSCs) | Related MSC | 0 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting at Least One, Grade 3 and Related Medically Significant Conditions (MSCs) | Grade 3 MSC | 0 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | Number of Subjects Reporting at Least One, Grade 3 and Related Medically Significant Conditions (MSCs) | At least one MSC | 5 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting at Least One, Grade 3 and Related Medically Significant Conditions (MSCs) | Related MSC | 0 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting at Least One, Grade 3 and Related Medically Significant Conditions (MSCs) | At least one MSC | 1 subjects |
| Fluarix Elderly Group | Number of Subjects Reporting at Least One, Grade 3 and Related Medically Significant Conditions (MSCs) | Grade 3 MSC | 0 subjects |
| Fluarix Young Group | Number of Subjects Reporting at Least One, Grade 3 and Related Medically Significant Conditions (MSCs) | Grade 3 MSC | 1 subjects |
| Fluarix Young Group | Number of Subjects Reporting at Least One, Grade 3 and Related Medically Significant Conditions (MSCs) | At least one MSC | 2 subjects |
| Fluarix Young Group | Number of Subjects Reporting at Least One, Grade 3 and Related Medically Significant Conditions (MSCs) | Related MSC | 0 subjects |
Secondary
Haemagglutination Inhibition (HI) Antibody Titers
Antibody titers were expressed as Geometric mean titers (GMTs). The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Days 0 and 21
Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity were available at day 21.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain at Day 0 (N=52; 39; 38) | 8.5 titer |
| Adjuvanted Influenza Vaccine GSK576389A Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain at Day 21 (N=51; 39; 38) | 91.6 titer |
| Adjuvanted Influenza Vaccine GSK576389A Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain at Day 0 (N=52; 39; 38) | 141.9 titer |
| Adjuvanted Influenza Vaccine GSK576389A Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain at Day 21 (N=51; 39; 38) | 384.5 titer |
| Adjuvanted Influenza Vaccine GSK576389A Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain at Day 0 (N=52; 39; 38) | 82.6 titer |
| Adjuvanted Influenza Vaccine GSK576389A Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain at Day 21 (N=51; 39; 38) | 163.2 titer |
| Fluarix Elderly Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain at Day 21 (N=51; 39; 38) | 93.8 titer |
| Fluarix Elderly Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain at Day 0 (N=52; 39; 38) | 6.9 titer |
| Fluarix Elderly Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain at Day 21 (N=51; 39; 38) | 147.6 titer |
| Fluarix Elderly Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain at Day 0 (N=52; 39; 38) | 59.6 titer |
| Fluarix Elderly Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain at Day 21 (N=51; 39; 38) | 30.3 titer |
| Fluarix Elderly Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain at Day 0 (N=52; 39; 38) | 70.6 titer |
| Fluarix Young Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain at Day 21 (N=51; 39; 38) | 110.0 titer |
| Fluarix Young Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain at Day 0 (N=52; 39; 38) | 115.1 titer |
| Fluarix Young Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain at Day 21 (N=51; 39; 38) | 210.3 titer |
| Fluarix Young Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Wisconsin strain at Day 21 (N=51; 39; 38) | 190.1 titer |
| Fluarix Young Group | Haemagglutination Inhibition (HI) Antibody Titers | A/Solomon Islands strain at Day 0 (N=52; 39; 38) | 56.0 titer |
| Fluarix Young Group | Haemagglutination Inhibition (HI) Antibody Titers | B/Malaysia strain at Day 0 (N=52; 39; 38) | 139.4 titer |
Secondary
HI Antibody Seroconversion Factors (SCF)
SCF was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Day 21
Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity were available at day 21.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group | HI Antibody Seroconversion Factors (SCF) | A/Solomon Islands strain | 10.6 fold increase |
| Adjuvanted Influenza Vaccine GSK576389A Group | HI Antibody Seroconversion Factors (SCF) | A/Wisconsin strain | 2.7 fold increase |
| Adjuvanted Influenza Vaccine GSK576389A Group | HI Antibody Seroconversion Factors (SCF) | B/Malaysia strain | 2.0 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors (SCF) | B/Malaysia strain | 1.6 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors (SCF) | A/Wisconsin strain | 2.1 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors (SCF) | A/Solomon Islands strain | 4.4 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors (SCF) | A/Wisconsin strain | 1.7 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors (SCF) | B/Malaysia strain | 1.5 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors (SCF) | A/Solomon Islands strain | 2.0 fold increase |
Secondary
The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker
The vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and Pool FLU antigens and the markers assessed were Cluster of Differentiation 4-All doubles i.e. CD4-All doubles, CD40 Ligand (CD40L), interferon-gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α).
Time frame: At Days 0 and 21
Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity were available at day 21.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-CD40L] D0 (N=44;36;35) | 1941.32 CD4 cells/10^6 CD4+ cells | Standard Deviation 1283.08 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-IFNγ] D21 (N=44;36;35) | 444.36 CD4 cells/10^6 CD4+ cells | Standard Deviation 446.32 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-TFNα] D21 (N=44;36;35) | 765.11 CD4 cells/10^6 CD4+ cells | Standard Deviation 686.36 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-All doubles] D0 (N=44;35;36) | 448.88 CD4 cells/10^6 CD4+ cells | Standard Deviation 497.51 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-IFNγ] D0 (N=44;36;36) | 225.18 CD4 cells/10^6 CD4+ cells | Standard Deviation 246.92 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-IL2] D21 (N=44;36;35) | 836.51 CD4 cells/10^6 CD4+ cells | Standard Deviation 650.1 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-CD40L] D0 (N=44;36;36) | 987.45 CD4 cells/10^6 CD4+ cells | Standard Deviation 890.57 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4- TFNα] D21 (N=44;36;35) | 495.31 CD4 cells/10^6 CD4+ cells | Standard Deviation 410.07 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-IL2] D0 (N=44;36;36) | 861.71 CD4 cells/10^6 CD4+ cells | Standard Deviation 826.31 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-CD40L] D0 (N=44;35;36) | 429.49 CD4 cells/10^6 CD4+ cells | Standard Deviation 476.96 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-TFNα] D0 (N=44;36;36) | 700.87 CD4 cells/10^6 CD4+ cells | Standard Deviation 778.74 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-All doubles] D0(N=44;36;36) | 289.37 CD4 cells/10^6 CD4+ cells | Standard Deviation 316.11 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-CD40L] D21 (N=44;36;35) | 930.92 CD4 cells/10^6 CD4+ cells | Standard Deviation 790.99 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-CD40L] D0 (N=44;36;36) | 549.05 CD4 cells/10^6 CD4+ cells | Standard Deviation 509.04 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-All doubles] D21(N=44;36;35) | 700.62 CD4 cells/10^6 CD4+ cells | Standard Deviation 634.14 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-IL2] D0 (N=44;36;36) | 500.73 CD4 cells/10^6 CD4+ cells | Standard Deviation 465.55 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-CD40L] D0 (N=44;36;36) | 270.70 CD4 cells/10^6 CD4+ cells | Standard Deviation 307.98 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-All doubles] D0 (N=44;36;36) | 603.80 CD4 cells/10^6 CD4+ cells | Standard Deviation 540.62 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-All doubles] D21 (N=44;36;35) | 2115.03 CD4 cells/10^6 CD4+ cells | Standard Deviation 1368.5 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-All doubles] D21 (N=44;36;35) | 1020.35 CD4 cells/10^6 CD4+ cells | Standard Deviation 830.08 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-TFNα] D21 (N=44;36;35) | 1368.75 CD4 cells/10^6 CD4+ cells | Standard Deviation 1094.14 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-All doubles] D0 (N=44;36;36) | 1054.11 CD4 cells/10^6 CD4+ cells | Standard Deviation 945.41 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-All doubles] D21 (N=44;36;35) | 925.46 CD4 cells/10^6 CD4+ cells | Standard Deviation 607.25 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-IFNγ] D0 (N=44;36;36) | 702.42 CD4 cells/10^6 CD4+ cells | Standard Deviation 642.37 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4- IL2] D21 (N=44;36;35) | 837.64 CD4 cells/10^6 CD4+ cells | Standard Deviation 530.27 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-IL2] D21 (N=44;36;35) | 616.24 CD4 cells/10^6 CD4+ cells | Standard Deviation 527.94 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-IFNγ] D21 (N=44;36;35) | 1231.82 CD4 cells/10^6 CD4+ cells | Standard Deviation 926.67 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-IL2] D21 (N=44;36;35) | 1711.92 CD4 cells/10^6 CD4+ cells | Standard Deviation 1141.42 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-IFNγ] D21 (N=44;36;35) | 565.96 CD4 cells/10^6 CD4+ cells | Standard Deviation 386.51 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-IL2] D0 (N=44;36;36) | 253.44 CD4 cells/10^6 CD4+ cells | Standard Deviation 281.09 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-CD40L] D21 (N=44;36;35) | 858.29 CD4 cells/10^6 CD4+ cells | Standard Deviation 562.66 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-IFNγ] D0 (N=44;35;36) | 314.05 CD4 cells/10^6 CD4+ cells | Standard Deviation 343.68 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-IFNγ] D21 (N=44;36;35) | 594.70 CD4 cells/10^6 CD4+ cells | Standard Deviation 547.1 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-TFNα] D0 (N=44;36;36) | 213.84 CD4 cells/10^6 CD4+ cells | Standard Deviation 261.37 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-CD40L] D21(N=44;36;35) | 642.40 CD4 cells/10^6 CD4+ cells | Standard Deviation 596.29 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4- TFNα] D0 (N=44;35;36) | 257.07 CD4 cells/10^6 CD4+ cells | Standard Deviation 342.41 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-TFNα] D21 (N=44;36;35) | 438.22 CD4 cells/10^6 CD4+ cells | Standard Deviation 458.26 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4- IL2] D0 (N=44;35;36) | 423.52 CD4 cells/10^6 CD4+ cells | Standard Deviation 454.12 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-IFNγ] D0 (N=44;36;36) | 327.24 CD4 cells/10^6 CD4+ cells | Standard Deviation 327.82 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-TFNα] D0 (N=44;36;36) | 505.57 CD4 cells/10^6 CD4+ cells | Standard Deviation 480.19 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4- IL2] D0 (N=44;35;36) | 317.95 CD4 cells/10^6 CD4+ cells | Standard Deviation 314.42 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-All doubles] D21 (N=44;36;35) | 776.74 CD4 cells/10^6 CD4+ cells | Standard Deviation 654.62 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-All doubles] D0 (N=44;36;36) | 983.41 CD4 cells/10^6 CD4+ cells | Standard Deviation 598.15 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-CD40L] D21(N=44;36;35) | 302.95 CD4 cells/10^6 CD4+ cells | Standard Deviation 473.99 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-CD40L] D21 (N=44;36;35) | 709.71 CD4 cells/10^6 CD4+ cells | Standard Deviation 622.14 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-CD40L] D0 (N=44;35;36) | 332.83 CD4 cells/10^6 CD4+ cells | Standard Deviation 337.05 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-CD40L] D0 (N=44;36;36) | 923.21 CD4 cells/10^6 CD4+ cells | Standard Deviation 555.48 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-CD40L] D0 (N=44;36;35) | 1399.44 CD4 cells/10^6 CD4+ cells | Standard Deviation 1125.57 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-IFNγ] D21 (N=44;36;35) | 297.00 CD4 cells/10^6 CD4+ cells | Standard Deviation 380.68 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-IFNγ] D21 (N=44;36;35) | 425.95 CD4 cells/10^6 CD4+ cells | Standard Deviation 366.97 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-IFNγ] D21 (N=44;36;35) | 395.62 CD4 cells/10^6 CD4+ cells | Standard Deviation 445.62 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-IFNγ] D0 (N=44;36;36) | 575.66 CD4 cells/10^6 CD4+ cells | Standard Deviation 442.31 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-IFNγ] D21 (N=44;36;35) | 892.48 CD4 cells/10^6 CD4+ cells | Standard Deviation 794.53 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-IL2] D0 (N=44;36;36) | 146.65 CD4 cells/10^6 CD4+ cells | Standard Deviation 216.35 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-TFNα] D0 (N=44;36;36) | 157.07 CD4 cells/10^6 CD4+ cells | Standard Deviation 191.42 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-TFNα] D21 (N=44;36;35) | 200.94 CD4 cells/10^6 CD4+ cells | Standard Deviation 422.7 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-TFNα] D0 (N=44;36;36) | 398.34 CD4 cells/10^6 CD4+ cells | Standard Deviation 330.78 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-TFNα] D21 (N=44;36;35) | 567.86 CD4 cells/10^6 CD4+ cells | Standard Deviation 528.7 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4- TFNα] D0 (N=44;35;36) | 180.31 CD4 cells/10^6 CD4+ cells | Standard Deviation 263.66 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4- TFNα] D21 (N=44;36;35) | 304.21 CD4 cells/10^6 CD4+ cells | Standard Deviation 460.57 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-All doubles] D0(N=44;36;36) | 180.39 CD4 cells/10^6 CD4+ cells | Standard Deviation 228.07 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-All doubles] D21(N=44;36;35) | 337.23 CD4 cells/10^6 CD4+ cells | Standard Deviation 500.65 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-All doubles] D0 (N=44;35;36) | 381.99 CD4 cells/10^6 CD4+ cells | Standard Deviation 341.08 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-All doubles] D21 (N=44;36;35) | 681.59 CD4 cells/10^6 CD4+ cells | Standard Deviation 593.45 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-All doubles] D21 (N=44;36;35) | 1509.46 CD4 cells/10^6 CD4+ cells | Standard Deviation 1159.17 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-CD40L] D0 (N=44;36;36) | 165.45 CD4 cells/10^6 CD4+ cells | Standard Deviation 211.89 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-CD40L] D0 (N=44;36;36) | 447.08 CD4 cells/10^6 CD4+ cells | Standard Deviation 404.96 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-CD40L] D21 (N=44;36;35) | 648.87 CD4 cells/10^6 CD4+ cells | Standard Deviation 571.71 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-IFNγ] D0 (N=44;36;36) | 178.68 CD4 cells/10^6 CD4+ cells | Standard Deviation 209.78 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-IFNγ] D0 (N=44;36;36) | 280.71 CD4 cells/10^6 CD4+ cells | Standard Deviation 243.51 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-IFNγ] D0 (N=44;35;36) | 254.50 CD4 cells/10^6 CD4+ cells | Standard Deviation 268.96 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-IL2] D21 (N=44;36;35) | 386.68 CD4 cells/10^6 CD4+ cells | Standard Deviation 403.33 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-IL2] D0 (N=44;36;36) | 425.33 CD4 cells/10^6 CD4+ cells | Standard Deviation 377.19 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-IL2] D21 (N=44;36;35) | 649.78 CD4 cells/10^6 CD4+ cells | Standard Deviation 561.75 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-All doubles] D0 (N=44;36;36) | 489.94 CD4 cells/10^6 CD4+ cells | Standard Deviation 426.96 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4- IL2] D21 (N=44;36;35) | 609.36 CD4 cells/10^6 CD4+ cells | Standard Deviation 501.15 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-IL2] D0 (N=44;36;36) | 852.92 CD4 cells/10^6 CD4+ cells | Standard Deviation 562.42 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-IL2] D21 (N=44;36;35) | 1253.42 CD4 cells/10^6 CD4+ cells | Standard Deviation 962.58 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-TFNα] D0 (N=44;36;36) | 687.37 CD4 cells/10^6 CD4+ cells | Standard Deviation 473.04 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-TFNα] D21 (N=44;36;35) | 1016.67 CD4 cells/10^6 CD4+ cells | Standard Deviation 899.04 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-TFNα] D21 (N=44;36;35) | 787.77 CD4 cells/10^6 CD4+ cells | Standard Deviation 804.78 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-CD40L] D0 (N=44;36;36) | 851.31 CD4 cells/10^6 CD4+ cells | Standard Deviation 663.11 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-IFNγ] D0 (N=44;36;36) | 321.79 CD4 cells/10^6 CD4+ cells | Standard Deviation 394.96 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-TFNα] D0 (N=44;36;36) | 626.76 CD4 cells/10^6 CD4+ cells | Standard Deviation 667.79 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-IFNγ] D21 (N=44;36;35) | 276.77 CD4 cells/10^6 CD4+ cells | Standard Deviation 478.52 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-TFNα] D21 (N=44;36;35) | 234.56 CD4 cells/10^6 CD4+ cells | Standard Deviation 509.44 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-TFNα] D0 (N=44;36;36) | 1236.53 CD4 cells/10^6 CD4+ cells | Standard Deviation 885.31 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-IFNγ] D0 (N=44;36;36) | 431.80 CD4 cells/10^6 CD4+ cells | Standard Deviation 490.54 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4- IL2] D0 (N=44;35;36) | 598.54 CD4 cells/10^6 CD4+ cells | Standard Deviation 495.94 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-IL2] D0 (N=44;36;36) | 314.65 CD4 cells/10^6 CD4+ cells | Standard Deviation 418.81 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-IL2] D0 (N=44;36;36) | 1398.63 CD4 cells/10^6 CD4+ cells | Standard Deviation 889.24 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-IFNγ] D0 (N=44;35;36) | 471.54 CD4 cells/10^6 CD4+ cells | Standard Deviation 429.46 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-IFNγ] D21 (N=44;36;35) | 1108.49 CD4 cells/10^6 CD4+ cells | Standard Deviation 956.85 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-IFNγ] D21 (N=44;36;35) | 612.24 CD4 cells/10^6 CD4+ cells | Standard Deviation 529.06 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-IFNγ] D0 (N=44;36;36) | 924.86 CD4 cells/10^6 CD4+ cells | Standard Deviation 704.75 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-All doubles] D0 (N=44;36;36) | 1693.14 CD4 cells/10^6 CD4+ cells | Standard Deviation 1045.17 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-IL2] D21 (N=44;36;35) | 278.09 CD4 cells/10^6 CD4+ cells | Standard Deviation 479.01 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-IFNγ] D21 (N=44;36;35) | 374.53 CD4 cells/10^6 CD4+ cells | Standard Deviation 618.57 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-All doubles] D21 (N=44;36;35) | 868.45 CD4 cells/10^6 CD4+ cells | Standard Deviation 946.28 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-IL2] D0 (N=44;36;36) | 735.18 CD4 cells/10^6 CD4+ cells | Standard Deviation 560.2 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-CD40L] D0 (N=44;36;35) | 1891.90 CD4 cells/10^6 CD4+ cells | Standard Deviation 1180.76 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-IL2] D21 (N=44;36;35) | 1643.55 CD4 cells/10^6 CD4+ cells | Standard Deviation 1047.94 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-IL2] D21 (N=44;36;35) | 507.19 CD4 cells/10^6 CD4+ cells | Standard Deviation 747.26 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-CD40L] D0 (N=44;36;36) | 1625.21 CD4 cells/10^6 CD4+ cells | Standard Deviation 968.97 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-All doubles] D21 (N=44;36;35) | 786.37 CD4 cells/10^6 CD4+ cells | Standard Deviation 723.64 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-All doubles] D0 (N=44;35;36) | 566.22 CD4 cells/10^6 CD4+ cells | Standard Deviation 581.71 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-All doubles] D0 (N=44;36;36) | 905.24 CD4 cells/10^6 CD4+ cells | Standard Deviation 750.96 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-TFNα] D0 (N=44;36;36) | 257.79 CD4 cells/10^6 CD4+ cells | Standard Deviation 414.2 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-All doubles] D21 (N=44;36;35) | 1998.24 CD4 cells/10^6 CD4+ cells | Standard Deviation 1287.85 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-All doubles] D21(N=44;36;35) | 258.27 CD4 cells/10^6 CD4+ cells | Standard Deviation 637.94 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD4-CD40L] D21 (N=44;36;35) | 726.97 CD4 cells/10^6 CD4+ cells | Standard Deviation 809.91 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-CD40L] D0 (N=44;36;36) | 309.92 CD4 cells/10^6 CD4+ cells | Standard Deviation 437.51 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-CD40L] D21(N=44;36;35) | 236.63 CD4 cells/10^6 CD4+ cells | Standard Deviation 553.12 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD4-All doubles] D0(N=44;36;36) | 331.14 CD4 cells/10^6 CD4+ cells | Standard Deviation 494.08 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD4-TFNα] D21 (N=44;36;35) | 1356.89 CD4 cells/10^6 CD4+ cells | Standard Deviation 1093.09 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4- TFNα] D21 (N=44;36;35) | 494.64 CD4 cells/10^6 CD4+ cells | Standard Deviation 550.12 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-CD40L] D0 (N=44;35;36) | 595.14 CD4 cells/10^6 CD4+ cells | Standard Deviation 562.39 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4- IL2] D21 (N=44;36;35) | 797.20 CD4 cells/10^6 CD4+ cells | Standard Deviation 619.24 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4-CD40L] D21 (N=44;36;35) | 748.64 CD4 cells/10^6 CD4+ cells | Standard Deviation 673.49 |
| Fluarix Young Group | The Geometric Mean (GM) Number of CD4 T-cells Per Million CD4+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD4- TFNα] D0 (N=44;35;36) | 381.85 CD4 cells/10^6 CD4+ cells | Standard Deviation 435.63 |
Secondary
The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker
The vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and Pool FLU antigens and the markers assessed were CD8-All doubles, CD40L, IFN-γ, IL-2 and TNF-α.
Time frame: At Days 0 and 21
Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity were available at day 21.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-CD40L] D0 (N=43;36;36) | 2.14 CD8 cells/10^6 CD8+ cells | Standard Deviation 32.9 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-All doubles] D21 (N=44;36;35) | 2.04 CD8 cells/10^6 CD8+ cells | Standard Deviation 65.79 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-All doubles] D0 (N=44;36;36) | 2.26 CD8 cells/10^6 CD8+ cells | Standard Deviation 136.77 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-All doubles] D21 (N=44;36;35 | 1.84 CD8 cells/10^6 CD8+ cells | Standard Deviation 88.15 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-All doubles] D0 (N=43;36;36) | 2.75 CD8 cells/10^6 CD8+ cells | Standard Deviation 60.5 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-All doubles] D0 (N=44;35;36) | 3.28 CD8 cells/10^6 CD8+ cells | Standard Deviation 159 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-All doubles] D21 (N=44;36;35) | 3.03 CD8 cells/10^6 CD8+ cells | Standard Deviation 89.02 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-All doubles] D0 (N=44;36;36) | 8.91 CD8 cells/10^6 CD8+ cells | Standard Deviation 213.18 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-All doubles] D21 (N=44;36;35) | 9.98 CD8 cells/10^6 CD8+ cells | Standard Deviation 149.19 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-CD40L] D0 (N=44;36;36) | 2.17 CD8 cells/10^6 CD8+ cells | Standard Deviation 124.96 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-CD40L] D21 (N=44;36;35) | 1.43 CD8 cells/10^6 CD8+ cells | Standard Deviation 40.8 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-CD40L] D21 (N=44;36;35) | 1.52 CD8 cells/10^6 CD8+ cells | Standard Deviation 45.12 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-CD40L] D0 (N=44;35;36) | 3.44 CD8 cells/10^6 CD8+ cells | Standard Deviation 150.26 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-CD40L] D21 (N=44;36;35) | 2.49 CD8 cells/10^6 CD8+ cells | Standard Deviation 90.52 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-CD40L] D0 (N=44;36;36) | 7.70 CD8 cells/10^6 CD8+ cells | Standard Deviation 171.7 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-CD40L] D21 (N=44;36;35) | 4.92 CD8 cells/10^6 CD8+ cells | Standard Deviation 129.03 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-IFNγ] D0 (N=44;36;36) | 2.07 CD8 cells/10^6 CD8+ cells | Standard Deviation 36.81 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-IFNγ] D21 (N=44;36;35) | 1.77 CD8 cells/10^6 CD8+ cells | Standard Deviation 72.15 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-IFNγ] D0 (N=43;36;36) | 1.71 CD8 cells/10^6 CD8+ cells | Standard Deviation 31.52 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-IFNγ] D21 (N=44;36;35) | 1.80 CD8 cells/10^6 CD8+ cells | Standard Deviation 26.18 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-IFNγ] D0 (N=44;35;36) | 1.93 CD8 cells/10^6 CD8+ cells | Standard Deviation 47.54 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-IFNγ] D21 (N=44;36;35) | 2.15 CD8 cells/10^6 CD8+ cells | Standard Deviation 35.22 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-IFNγ] D0 (N=44;36;36) | 2.86 CD8 cells/10^6 CD8+ cells | Standard Deviation 46.18 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-IFNγ] D21 (N=44;36;35) | 2.55 CD8 cells/10^6 CD8+ cells | Standard Deviation 47.59 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-IL2] D0 (N=44;36;36) | 2.17 CD8 cells/10^6 CD8+ cells | Standard Deviation 135.16 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-IL2] D21 (N=44;36;35) | 1.54 CD8 cells/10^6 CD8+ cells | Standard Deviation 76.05 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-IL2] D0 (N=43;36;36) | 2.55 CD8 cells/10^6 CD8+ cells | Standard Deviation 65.54 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-IL2] D21 (N=44;36;35) | 2.30 CD8 cells/10^6 CD8+ cells | Standard Deviation 65.28 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-IL2] D0 (N=44;35;36) | 2.35 CD8 cells/10^6 CD8+ cells | Standard Deviation 136.2 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-IL2] D21 (N=44;36;35) | 3.12 CD8 cells/10^6 CD8+ cells | Standard Deviation 97.43 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-IL2] D0 (N=44;36;36) | 7.71 CD8 cells/10^6 CD8+ cells | Standard Deviation 210.95 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-IL2] D21 (N=44;36;35) | 9.19 CD8 cells/10^6 CD8+ cells | Standard Deviation 155.66 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-TFNα] D0 (N=44;36;36) | 2.42 CD8 cells/10^6 CD8+ cells | Standard Deviation 49.99 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-TFNα] D21 (N=44;36;35) | 1.97 CD8 cells/10^6 CD8+ cells | Standard Deviation 68.53 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-TFNα] D0 (N=43;36;36) | 3.54 CD8 cells/10^6 CD8+ cells | Standard Deviation 76.4 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-TFNα] D21 (N=44;36;35) | 2.84 CD8 cells/10^6 CD8+ cells | Standard Deviation 42.13 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-TFNα] D0 (N=44;35;36) | 2.73 CD8 cells/10^6 CD8+ cells | Standard Deviation 80.16 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-TFNα] D21 (N=44;36;35) | 2.76 CD8 cells/10^6 CD8+ cells | Standard Deviation 52.39 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-TFNα] D0 (N=44;36;36) | 6.74 CD8 cells/10^6 CD8+ cells | Standard Deviation 92.88 |
| Adjuvanted Influenza Vaccine GSK576389A Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-TFNα] D21 (N=44;36;35) | 5.86 CD8 cells/10^6 CD8+ cells | Standard Deviation 58.58 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-CD40L] D21 (N=44;36;35) | 1.62 CD8 cells/10^6 CD8+ cells | Standard Deviation 40.21 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-IL2] D21 (N=44;36;35) | 8.89 CD8 cells/10^6 CD8+ cells | Standard Deviation 149.48 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-CD40L] D0 (N=44;36;36) | 6.52 CD8 cells/10^6 CD8+ cells | Standard Deviation 67.52 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-CD40L] D21 (N=44;36;35) | 4.64 CD8 cells/10^6 CD8+ cells | Standard Deviation 135.66 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-TFNα] D21 (N=44;36;35) | 3.42 CD8 cells/10^6 CD8+ cells | Standard Deviation 64.32 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-IFNγ] D0 (N=44;36;36) | 1.49 CD8 cells/10^6 CD8+ cells | Standard Deviation 49.87 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-TFNα] D0 (N=44;36;36) | 1.99 CD8 cells/10^6 CD8+ cells | Standard Deviation 70.11 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-IFNγ] D21 (N=44;36;35) | 2.12 CD8 cells/10^6 CD8+ cells | Standard Deviation 38.86 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-IFNγ] D0 (N=43;36;36) | 2.76 CD8 cells/10^6 CD8+ cells | Standard Deviation 45.51 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-IFNγ] D21 (N=44;36;35) | 2.73 CD8 cells/10^6 CD8+ cells | Standard Deviation 55.42 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-TFNα] D21 (N=44;36;35) | 2.40 CD8 cells/10^6 CD8+ cells | Standard Deviation 41.63 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-IFNγ] D0 (N=44;35;36) | 2.75 CD8 cells/10^6 CD8+ cells | Standard Deviation 135.21 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-IFNγ] D21 (N=44;36;35) | 2.24 CD8 cells/10^6 CD8+ cells | Standard Deviation 59.72 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-TFNα] D21 (N=44;36;35) | 5.55 CD8 cells/10^6 CD8+ cells | Standard Deviation 104.44 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-IFNγ] D0 (N=44;36;36) | 2.48 CD8 cells/10^6 CD8+ cells | Standard Deviation 50.62 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-TFNα] D0 (N=43;36;36) | 5.58 CD8 cells/10^6 CD8+ cells | Standard Deviation 70.98 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-IFNγ] D21 (N=44;36;35) | 4.17 CD8 cells/10^6 CD8+ cells | Standard Deviation 75.18 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-IL2] D0 (N=44;36;36) | 3.16 CD8 cells/10^6 CD8+ cells | Standard Deviation 92.06 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-TFNα] D0 (N=44;36;36) | 8.70 CD8 cells/10^6 CD8+ cells | Standard Deviation 72.98 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-IL2] D21 (N=44;36;35) | 1.46 CD8 cells/10^6 CD8+ cells | Standard Deviation 28.82 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-TFNα] D21 (N=44;36;35) | 2.76 CD8 cells/10^6 CD8+ cells | Standard Deviation 65.68 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-IL2] D0 (N=43;36;36) | 4.58 CD8 cells/10^6 CD8+ cells | Standard Deviation 263.11 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-All doubles] D0 (N=43;36;36) | 5.30 CD8 cells/10^6 CD8+ cells | Standard Deviation 264.71 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-IL2] D21 (N=44;36;35) | 1.87 CD8 cells/10^6 CD8+ cells | Standard Deviation 46.74 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-All doubles] D0 (N=44;36;36) | 3.28 CD8 cells/10^6 CD8+ cells | Standard Deviation 101.08 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-All doubles] D21 (N=44;36;35 | 1.92 CD8 cells/10^6 CD8+ cells | Standard Deviation 55.86 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-All doubles] D21 (N=44;36;35) | 2.55 CD8 cells/10^6 CD8+ cells | Standard Deviation 54.17 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-IL2] D0 (N=44;35;36) | 3.18 CD8 cells/10^6 CD8+ cells | Standard Deviation 142.54 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-All doubles] D0 (N=44;35;36) | 4.12 CD8 cells/10^6 CD8+ cells | Standard Deviation 154.66 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-All doubles] D21 (N=44;36;35) | 2.69 CD8 cells/10^6 CD8+ cells | Standard Deviation 83.37 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-TFNα] D0 (N=44;35;36) | 8.42 CD8 cells/10^6 CD8+ cells | Standard Deviation 104.25 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-All doubles] D0 (N=44;36;36) | 10.47 CD8 cells/10^6 CD8+ cells | Standard Deviation 89.43 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-IL2] D21 (N=44;36;35) | 2.36 CD8 cells/10^6 CD8+ cells | Standard Deviation 73.1 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-All doubles] D21 (N=44;36;35) | 8.02 CD8 cells/10^6 CD8+ cells | Standard Deviation 158.53 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-CD40L] D0 (N=44;36;36) | 1.97 CD8 cells/10^6 CD8+ cells | Standard Deviation 88.18 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-CD40L] D21 (N=44;36;35) | 1.64 CD8 cells/10^6 CD8+ cells | Standard Deviation 30.98 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-CD40L] D0 (N=43;36;36) | 2.67 CD8 cells/10^6 CD8+ cells | Standard Deviation 222.75 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-IL2] D0 (N=44;36;36) | 8.20 CD8 cells/10^6 CD8+ cells | Standard Deviation 96.31 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-CD40L] D21 (N=44;36;35) | 1.68 CD8 cells/10^6 CD8+ cells | Standard Deviation 40.13 |
| Fluarix Elderly Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-CD40L] D0 (N=44;35;36) | 2.27 CD8 cells/10^6 CD8+ cells | Standard Deviation 96.08 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-IL2] D0 (N=43;36;36) | 1.69 CD8 cells/10^6 CD8+ cells | Standard Deviation 30.56 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-CD40L] D21 (N=44;36;35) | 2.59 CD8 cells/10^6 CD8+ cells | Standard Deviation 45.37 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-TFNα] D21 (N=44;36;35) | 4.56 CD8 cells/10^6 CD8+ cells | Standard Deviation 70.82 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-All doubles] D0 (N=43;36;36) | 2.44 CD8 cells/10^6 CD8+ cells | Standard Deviation 39.72 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-CD40L] D0 (N=44;36;36) | 4.42 CD8 cells/10^6 CD8+ cells | Standard Deviation 49.26 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-IL2] D21 (N=44;36;35) | 5.36 CD8 cells/10^6 CD8+ cells | Standard Deviation 73.11 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-TFNα] D21 (N=44;36;35) | 2.19 CD8 cells/10^6 CD8+ cells | Standard Deviation 48.45 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-CD40L] D21 (N=44;36;35) | 3.41 CD8 cells/10^6 CD8+ cells | Standard Deviation 60.34 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-All doubles] D21 (N=44;36;35) | 6.50 CD8 cells/10^6 CD8+ cells | Standard Deviation 95.79 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-IL2] D21 (N=44;36;35) | 3.69 CD8 cells/10^6 CD8+ cells | Standard Deviation 50.07 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-IFNγ] D0 (N=44;36;36) | 3.15 CD8 cells/10^6 CD8+ cells | Standard Deviation 173.1 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-All doubles] D0 (N=44;36;36) | 4.14 CD8 cells/10^6 CD8+ cells | Standard Deviation 186.27 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-IL2] D21 (N=44;36;35) | 2.95 CD8 cells/10^6 CD8+ cells | Standard Deviation 74.62 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-IFNγ] D21 (N=44;36;35) | 3.53 CD8 cells/10^6 CD8+ cells | Standard Deviation 113.89 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-TFNα] D0 (N=44;36;36) | 3.75 CD8 cells/10^6 CD8+ cells | Standard Deviation 175.1 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-CD40L] D0 (N=44;35;36) | 2.49 CD8 cells/10^6 CD8+ cells | Standard Deviation 57.45 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-IFNγ] D0 (N=43;36;36) | 1.27 CD8 cells/10^6 CD8+ cells | Standard Deviation 16.73 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-TFNα] D21 (N=44;36;35) | 1.66 CD8 cells/10^6 CD8+ cells | Standard Deviation 30.79 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-TFNα] D0 (N=44;36;36) | 3.32 CD8 cells/10^6 CD8+ cells | Standard Deviation 142.5 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-IFNγ] D21 (N=44;36;35) | 1.88 CD8 cells/10^6 CD8+ cells | Standard Deviation 33.19 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-CD40L] D0 (N=44;36;36) | 1.61 CD8 cells/10^6 CD8+ cells | Standard Deviation 22.41 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-All doubles] D21 (N=44;36;35) | 3.69 CD8 cells/10^6 CD8+ cells | Standard Deviation 62.67 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-IFNγ] D0 (N=44;35;36) | 2.43 CD8 cells/10^6 CD8+ cells | Standard Deviation 53.85 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-TFNα] D21 (N=44;36;35) | 2.99 CD8 cells/10^6 CD8+ cells | Standard Deviation 132.56 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-TFNα] D0 (N=44;35;36) | 2.38 CD8 cells/10^6 CD8+ cells | Standard Deviation 72.34 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-IFNγ] D21 (N=44;36;35) | 1.47 CD8 cells/10^6 CD8+ cells | Standard Deviation 19.69 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-CD40L] D21 (N=44;36;35) | 2.55 CD8 cells/10^6 CD8+ cells | Standard Deviation 44.6 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-All doubles] D0 (N=44;35;36) | 2.39 CD8 cells/10^6 CD8+ cells | Standard Deviation 72.34 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-IFNγ] D0 (N=44;36;36) | 3.88 CD8 cells/10^6 CD8+ cells | Standard Deviation 117.16 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-IL2] D0 (N=44;35;36) | 1.90 CD8 cells/10^6 CD8+ cells | Standard Deviation 32.04 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-CD40L] D21 (N=44;36;35) | 1.94 CD8 cells/10^6 CD8+ cells | Standard Deviation 47.82 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-IFNγ] D21 (N=44;36;35) | 2.57 CD8 cells/10^6 CD8+ cells | Standard Deviation 50.74 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-TFNα] D0 (N=43;36;36) | 2.44 CD8 cells/10^6 CD8+ cells | Standard Deviation 44.31 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | B/Malaysia[CD8-All doubles] D21 (N=44;36;35) | 2.28 CD8 cells/10^6 CD8+ cells | Standard Deviation 44.43 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-IL2] D0 (N=44;36;36) | 2.49 CD8 cells/10^6 CD8+ cells | Standard Deviation 125.6 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-All doubles] D21 (N=44;36;35 | 3.60 CD8 cells/10^6 CD8+ cells | Standard Deviation 138.6 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-IL2] D0 (N=44;36;36) | 6.61 CD8 cells/10^6 CD8+ cells | Standard Deviation 63.15 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Solomon Islands[CD8-IL2] D21 (N=44;36;35) | 4.26 CD8 cells/10^6 CD8+ cells | Standard Deviation 129.7 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | Pool FLU[CD8-All doubles] D0 (N=44;36;36) | 9.43 CD8 cells/10^6 CD8+ cells | Standard Deviation 153.8 |
| Fluarix Young Group | The GM Number of CD8 T-cells Per Million CD8+ T-cells for Each Vaccine Strain and for Pooled Vaccine Strains Producing at Least Two Different Immune Markers or Producing Each of the Immune Markers Plus Another Immune Marker | A/Wisconsin[CD8-CD40L] D0 (N=43;36;36) | 1.70 CD8 cells/10^6 CD8+ cells | Standard Deviation 35.64 |
Secondary
The Number of Subjects Seroconverted to HI Antibodies
Seroconversion was defined as either a pre-vaccination titer \<1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Day 21
Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity were available at day 21.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seroconverted to HI Antibodies | B/Malaysia strain | 10 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seroconverted to HI Antibodies | A/Solomon Islands strain | 39 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seroconverted to HI Antibodies | A/Wisconsin strain | 18 subjects |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies | A/Solomon Islands strain | 19 subjects |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies | A/Wisconsin strain | 6 subjects |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies | B/Malaysia strain | 4 subjects |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies | B/Malaysia strain | 2 subjects |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies | A/Wisconsin strain | 4 subjects |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies | A/Solomon Islands strain | 6 subjects |
Secondary
The Number of Subjects Seropositive to HI Antibodies
Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e. ≥ 1:10. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Days 0 and 21
Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity were available at day 21.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seropositive to HI Antibodies | A/Solomon Islands strain at Day 0 (N=52; 39; 38) | 19 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seropositive to HI Antibodies | A/Solomon Islands strain at Day 21 (N=51; 39; 38) | 48 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seropositive to HI Antibodies | A/Wisconsin strain at Day 0 (N=52; 39; 38) | 50 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seropositive to HI Antibodies | A/Wisconsin strain at Day 21 (N=51; 39; 38) | 51 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seropositive to HI Antibodies | B/Malaysia strain at Day 0 (N=52; 39; 38) | 52 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seropositive to HI Antibodies | B/Malaysia strain at Day 21 (N=51; 39; 38) | 51 subjects |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies | B/Malaysia strain at Day 0 (N=52; 39; 38) | 38 subjects |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies | A/Wisconsin strain at Day 21 (N=51; 39; 38) | 39 subjects |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies | B/Malaysia strain at Day 21 (N=51; 39; 38) | 38 subjects |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies | A/Solomon Islands strain at Day 0 (N=52; 39; 38) | 12 subjects |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies | A/Wisconsin strain at Day 0 (N=52; 39; 38) | 37 subjects |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies | A/Solomon Islands strain at Day 21 (N=51; 39; 38) | 28 subjects |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies | A/Solomon Islands strain at Day 0 (N=52; 39; 38) | 33 subjects |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies | A/Solomon Islands strain at Day 21 (N=51; 39; 38) | 37 subjects |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies | B/Malaysia strain at Day 0 (N=52; 39; 38) | 37 subjects |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies | B/Malaysia strain at Day 21 (N=51; 39; 38) | 38 subjects |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies | A/Wisconsin strain at Day 0 (N=52; 39; 38) | 37 subjects |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies | A/Wisconsin strain at Day 21 (N=51; 39; 38) | 38 subjects |
Secondary
The Number of Subjects Seroprotected to HI Antibodies
Seroprotection was defined as serum HI titer ≥1:40 that usually is accepted as indicating protection. The vaccine strains included A/Solomon Islands, A/Wisconsin and B/Malaysia antigens.
Time frame: At Days 0 and 21
Population: Analysis was performed on According-to-Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity were available at day 21.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seroprotected to HI Antibodies | A/Solomon Islands strain at Day 0 (52; 39; 38) | 6 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seroprotected to HI Antibodies | A/Solomon Islands strain at Day 21 (51; 39; 38) | 42 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seroprotected to HI Antibodies | A/Wisconsin strain at Day 0 (N= 52; 39; 38) | 49 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seroprotected to HI Antibodies | A/Wisconsin strain at Day 21 (N= 51; 39; 38) | 50 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seroprotected to HI Antibodies | B/Malaysia strain at Day 0 (N=52; 39; 38) | 47 subjects |
| Adjuvanted Influenza Vaccine GSK576389A Group | The Number of Subjects Seroprotected to HI Antibodies | B/Malaysia strain at Day 21 (N=51; 39; 38) | 51 subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | B/Malaysia strain at Day 21 (N=51; 39; 38) | 37 subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | A/Solomon Islands strain at Day 0 (52; 39; 38) | 1 subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | A/Wisconsin strain at Day 21 (N= 51; 39; 38) | 35 subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | B/Malaysia strain at Day 0 (N=52; 39; 38) | 31 subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | A/Solomon Islands strain at Day 21 (51; 39; 38) | 21 subjects |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | A/Wisconsin strain at Day 0 (N= 52; 39; 38) | 31 subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | A/Solomon Islands strain at Day 21 (51; 39; 38) | 32 subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | A/Wisconsin strain at Day 0 (N= 52; 39; 38) | 33 subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | B/Malaysia strain at Day 21 (N=51; 39; 38) | 37 subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | A/Wisconsin strain at Day 21 (N= 51; 39; 38) | 37 subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | A/Solomon Islands strain at Day 0 (52; 39; 38) | 25 subjects |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | B/Malaysia strain at Day 0 (N=52; 39; 38) | 35 subjects |